Skip to content
Clinical Trials – home

Instituto De Microcirugia Ocular Dos S.L.

Verified siteinfo

Spain Calle De Josep Maria Llado 3, 08017 Barcelona, Spain

  • 4 trials recruiting
  • Dry age-related macular degeneration · Age-related macular degeneration · Diabetic retinal oedema
  • Adults and children

About Specializations

Instituto De Microcirugia Ocular Dos S.L. in Barcelona, Spain specialises in clinical trials of conditions such as Dry age-related macular degeneration, Age-related macular degeneration, Diabetic retinal oedema, Endocrine ophthalmopathy, and other specialisations. This site conducts important research.

Main research areas of the site

Retina and Eye Diseases

At Instituto De Microcirugia Ocular Dos S.L. in Barcelona, clinical research is centered on retinal and ocular diseases, with a strong focus on conditions that affect vision and eye health. The studies are designed to assess new treatments, compare them with established care, and better understand how to preserve or improve sight in people with chronic eye disorders.

  • Research in diabetic macular edema and diabetic retinopathy is evaluating whether new eye therapies can improve visual outcomes and reduce disease activity.
  • Trials in neovascular age-related macular degeneration are testing innovative approaches, including gene therapy and combination treatment strategies, to support vision preservation.
  • Studies in geographic atrophy secondary to age-related macular degeneration are examining new ways to slow lesion growth and assess long-term safety.
  • The site is also involved in research on thyroid eye disease, myopia, neurotrophic keratopathy, and persistent corneal epithelial defect, with the aim of improving symptom control and healing.

Overall, the Retina department is contributing to a broad range of ophthalmology studies that combine treatment testing, safety evaluation, and efforts to improve diagnosis and disease management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle De Josep Maria Llado 308017 BarcelonaSpain
Recruiting now
4 trials
Conditions studied
10
Partner status
Verified site

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

15 clinical trials

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Somatostatin
  • Sponsor:Bcn Peptides S.A.

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Study on the Safety and Effectiveness of Timbetasin Acetate Eye Drops for Patients with Neurotrophic Keratopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Timbetasin Acetate
  • Sponsor:Regentree LLC

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Long-Term Safety Study of GT005 for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration Previously Treated in a Gyroscope Study

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GT005
  • Sponsor:Novartis Pharma AG

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.